Objectives: The introduction of metagenomic sequencing to diagnostic microbiology has been hampered by slowness, cost and complexity. We explored whether MinION nanopore sequencing could accelerate diagnosis and resistance profiling, using complicated urinary tract infections as an exemplar.
Introduction
The UK Government's O ′ Neill Commission, reviewing the threat of antibiotic resistance, 1 stresses the potential of rapid diagnostics to improve both treatment and antibiotic stewardship. Reducing the time needed to obtain a microbiological diagnosis shortens the duration of broad empirical therapy and its selective pressures.
PCR can detect pathogens and resistance genes in specimens without culture, but cannot cover the diversity of organisms and resistance determinants potentially present. Metagenomic sequencing could deliver this comprehensiveness, 2 -7 but slow turnaround, cost and complexity have impeded introduction into clinical microbiology.
Oxford Nanopore Technologies ′ (ONT) MinION 8 is the first technology potentially able to deliver sequencing data from clinical samples in a timeframe allowing early de-escalation and refinement of antimicrobial treatment. We examined its applicability to investigation of urinary tract infections (UTIs). These account for over 8 million physician visits per annum in the USA. 9 Most are trivial, but, in severe cases, infection may ascend to the kidneys, with overspill to the bloodstream precipitating bacteraemia and urosepsis. Complicated UTIs are a growing cause of hospitalization, mostly of elderly patients, 10 and 35 676 Escherichia coli bloodstream infections were recorded in England in 2014 -15, 11 over 60% with a urinary origin. There is growing resistance, particularly in severe and bacteraemic infections, to fluoroquinolones, cephalosporins and lactamase-inhibitor combinations, driving use of previously reserved carbapenems, even as 'empirical' therapy. With carbapenemases now proliferating, and few alternative therapies in reserve, escalating empiricism becomes increasingly untenable, underscoring the desirability of moving to early targeted therapy, guided by diagnostics.
Materials and methods

Urines
Ten heavily infected (. 10 7 cfu/mL) clinical urines (CU1-10) from patients at the Norfolk and Norwich University Hospital (NNUH) were tested. Additionally, urine from a healthy volunteer was spiked with 10 8 cfu/mL of the MDR E. coli strain H141480453 and with cultivated E. coli from CU6. The genome sequence of E. coli H141480453 was determined previously (Illumina HiSeq) at Public Health England (PHE).
Ethics
Ethical approval was not required for the study as testing was performed, for method development purposes, on excess sample from routine CUs submitted to the Norfolk and Norwich University Hospital clinical microbiology laboratory and no patient information was collected.
Sample preparation for MinION Nanopore sequencing
Methodology was refined during the project. In its final iteration, urines (4-10 mL) were centrifuged at 300 g for 2 min to deplete human cells. The supernatant was collected and re-centrifuged at 12300 g for 5 min, with the resulting bacterial pellet resuspended in 1 mL of PBS and processed with a MolYsis Basic 5 Kit (MolYsis Life Science, Bremen, Germany) to lyse residual human cells and to remove their DNA. Bacterial Lysis Buffer (Roche, Basel, Switzerland) and proteinase K (14-22 mg/mL) (Roche) were added and, after incubation for 10 min at 658C, DNA was purified using the MagNA Pure Compact Nucleic Acid Isolation Kit (Roche) and DNA Bacteria v3_2 protocol. Variations, in early iterations, were (i) the initial centrifugation was omitted and no human DNA depletion performed (CU1), and (ii) a NEBNext w Microbiome DNA Enrichment kit (New England BioLabs, Hitchin, UK) was used to remove human DNA instead of MolYsis (CU2-4).
To spike urines, 1 mL of overnight broth culture (10 9 cfu/mL) was added to 9 mL of donor urine, which was then processed as above, always using the final iteration of the method.
The quality and concentration of DNA was assessed using a Qubit w 2.0 Fluorometer (Life Technologies, Paisley, UK) and 2200 TapeStation (Agilent Technologies, Santa Clara, CA); concentrations .15 mg/L were considered acceptable.
MinION library preparation and sequencing
To generate a library with an average fragment size of 8 kb, up to 2 mg of DNA was fragmented by centrifugation at 7200 rpm (3600 g) in a G-tube (Covaris, Brighton, UK), used according to the manufacturer's instructions, then end-repaired (New England BioLabs), cleaned with Agencourt AMPure XP Beads (Beckman Coulter, High Wycombe, UK) and dA-tailed (New England BioLabs). The product was re-cleaned and eluted in 31 mL of Tris-HCl (pH 8.5).
The library was then prepared according to the SQK-MAP-006 Genomic Sequencing Kit protocol provided by ONT. 12 Variations, in earlier library preparation experiments, were: (i) Kit SQK-MAP-002 was used for CU1 -4 13 ; (ii) Kit SQK-MAP-003 was used with CU5 and 6 and for spiked urine run 1 13 ; (iii) Kit SQK-MAP-004 was used 14 for CU7 and urine spiked with E. coli recovered from CU6; (iv) Kit SQK-MAP-005 8 was used with CU8-10 and spiked urine run 2; and (v) ONT Rapid Sequencing Kit, with a 15 min library preparation procedure, was used, in accordance with the manufacturer's instructions, for spiked urine run 4.
MinION sequencing was performed using R7.3 flow cells, except for CU1 -4, where R7.0 cells were used. Sequencing was run for 7.5 -48 h (see Table 1 ). ONT MinKNOW software (versions 0.45.2.6 -2.34.3) was used to collect raw electronic signal data, which were base-called using Metrichor TM software.
BLAST and CARD identification of pathogens and resistance genes using MinION data Identification of species and resistance genes routinely utilized BLAST search and the CARD (Comprehensive Antibiotic Resistance Database) database. 15 MinION data were extracted, in fasta format, from raw HDF5 files using Poretools. 16 BLAST database aliases were built for proteobacteria, firmicutes and human sequences. Top hits from each of these separate database aliases were identified. Taxa were distinguished using the in-house script blast_separate_taxa.pl and taxonomy was assigned using blast_taxonomy_report.pl 17 with some modifications. 18 Resistance genes were identified by aligning MinION reads to the CARD database using LAST, with parameters optimized for low-accuracy long matches. 19 -21 Some sequences in CARD contain resistance-gene-flanking regions, leading to false positive results, therefore putative matches were verified by visualization in Artemis (Sanger) 22, 23 and by examination of the coordinates. Consensus sequences were built upon the CARD database reference sequences using the MinION read alignments by Samtools 0.1.19, Samtools mpileup, bcftools, vcfutils.pl and vcf2fq, ultimately generating indexed Bam files. 24, 25 BLASTn (BLAST v 2.2.30+) top hits were identified, using consensus sequences, against the CARD database, seeking .80% identity over the length of a gene. In addition, reciprocal BLAST best-hits were identified between the consensus sequences and the CARD database. The resulting output data were parsed and sorted with a final report generated by a Python script.
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WIMP and ARMA alignment for pathogen identification and resistance gene detection
The ONT 'What's in my pot?' (WIMP) 26 Metrichor application identifies the uropathogen in real-time, using a reference database and Kraken 11; along with Metrichor's Antimicrobial Resistance Mapping Application (ARMA) 27 for real-time detection of antibiotic resistance genes. Both applications only became available toward the end of the study and were used for spiked urine run 3 only.
Illumina library preparation
Two methods were used to sequence DNA from the bacteria cultivated from the urines. At PHE's Genomic Services Unit, genomic DNA was prepared using a GeneJET Genomic DNA Purification Kit (ThermoFisher, Cambridge, UK) and sequenced on a HiSeq instrument (Illumina, Cambridge, UK) in Rapid Run mode. 28 The library was prepared using the Nextera XT DNA Sample Preparation kits (Illumina), following the manufacturer's protocol. At Brunel University, bacterial DNA was quantified using the Quant-iT TM PicoGreen w dsDNA Kits (Life Technology, Paisley, UK) and a FLUOstar OPTIMA plate scanner (BMG Labtech, Ortenberg, Germany) according to the manufacturers ′ specifications. DNA (300 ng) was fragmented using an Episonic system (Epigentek, New York, USA). Libraries were constructed using the NEBNext Ultra DNA Sample Prep Master Mix Kit (NEB) using an automated protocol on a Biomek FX instrument (Beckman Coulter). Ligation was performed with Illumina Adapters (Multiplexing Sample Preparation Oligonucleotide Kit) and ligated libraries were size-selected using Agencourt AMPure XP Beads (Beckman Coulter). Samples were sequenced on the 150 bp end Illumina HiSeq 2000 platform.
CARD alignment for resistance gene detection from cultivated bacteria
The presence of resistance genes in Illumina sequence reads was determined with 'Genefinder', an in-house PHE algorithm that uses bowtie2 29 to map the reads to a local database of antimicrobial resistance genes, and Samtools 0.1.18 24, 25 to generate an mpileup file. The script then parses the mpileup file to match to reference sequences, based on read coverage and .90% nucleotide identity over the full length of the sequence (the lower threshold adopted for MinION was because of higher expected error rates).
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Phenotypic characterization of uropathogens
Bacteria were grown by standard methodology 30 and identified by MALDI-TOF mass spectroscopy (Bruker, Bremen, Germany). MICs were determined at PHE by BSAC agar dilution, with results categorized using EUCAST criteria. 31 
Results
MinION results and performance improvement
Fifteen MinION runs were performed: 10 with CUs, four using urine spiked with E. coli H141480453 and one spiked with the E. coli from CU6 (Table 1) . Early attempts failed because human DNA was insufficiently depleted (CU1), flow cells were poor quality (CU2 and 4) or DNA was degraded (CU3). Improved sample and library preparation, along with R7.3 flow cells, resolved these issues (Figure 1) . From CU5 onwards, MinION produced 6536 -34 330 2-D reads/run, with 2518 -22405 'pass 2-D reads', and a mean read-length of 3452 -6076 bp. The longest single read was 46 213 bp, and single-read identity to reference sequences improved from 70% to 85%. Successive runs for urine spiked with E. coli H141480453 illustrate the gains ( Figure 2) ; sequence yield and depth improved from run 1 to 2; WIMP/ARMA software reduced processing to 7.5 h in run 3; this fell to 4 h in run 4 using the Rapid Library Preparation Kit, despite having to revert to BLAST/CARD analysis since WIMP/ARMA could not analyse the kits 1-D read data.
Bacterial identification
Analysis using BLAST and the CARD database was performed on 2-D 'pass' reads for CU5 -7 and for all spiked urines (except run 3, using WIMP/AMRA). For CU8 -10 we combined 2-D reads from 
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MinION sequencing for pathogen profiling JAC 'pass' and 'fail' folders. In all cases, MinION correctly identified the pathogen (Table 2) ; WIMP achieved this within 15 min. Human DNA accounted for only 1.6% -12.3% of reads, confirming that depletion was effective. Breadth of coverage was from 82.6% to 100%; depth was least for CU5 (2.71×) and greatest (21.55 -22.84×) for spiked urine run 2 and CU8 (Table 2) .
Resistance gene profiles
Acquired resistance genes were readily identified in MinION outputs, as illustrated in Figure 3 (CUs) and Table 3 (spiked urines). Among 55 acquired resistance genes detected by Illumina sequencing of the cultivated bacteria, 51 were found by MinION directly from urines; three of four exceptions were with CU5, where coverage was poorest. Limitations were: (i) MinION often flagged multiple gene variants, whereas Illumina definitively identified alleles; (ii) resistance-conferring mutations were not detected; and (iii) plasmid and chromosomal ampC were not discriminated and nor could the mode of ampC expression be inferred.
CU5 (Klebsiella pneumoniae)
MinION and Illumina detected bla CTX-M-15 corresponding to the isolate's ESBL phenotype. Both also found bla OXA-1 , congruent with amoxicillin/clavulanate resistance. Also in agreement, both found dfrA14, explaining trimethoprim resistance. Illumina identified bla LEN-12 and bla SHV-27 , whereas MinION indicated bla SHV-32 ; these probably all correspond to the chromosomal bla LEN /bla SHV of K. pneumoniae. Illumina also detected bla TEM-1 , which should not expand resistance in the presence of CTX-M-15. The strain was resistant to gentamicin and tobramycin, according with detection, by both MinION and Illumina, of aacC2; both methods also found aac(6 ′ )-Ib-cr, encoding a tobramycin-and amikacinmodifying enzyme. The low amikacin MIC (2 mg/L) does not conflict with this: EUCAST advocates reporting all isolates with AAC(6 ′ )-1b as amikacin non-susceptible irrespective of MIC. Streptomycin resistance agreed with the presence of strA (detected by both methods) and strB (found only by Illumina). Both approaches found qnrB and aac(6 ′ )-Ib-cr, according with low-level ciprofloxacin resistance (MIC, 2 mg/L).
CU6 (E. coli)
MinION and Illumina both found bla CTX-M-15 and bla OXA-1 , again congruent with an ESBL phenotype and amoxicillin/clavulanate resistance. Both also indicated bla TEM-1. MinION flagged several acquired ampC genes, whilst Illumina indicated bla CMY-113 and bla MIR-14 , albeit below the 90% threshold. It is likely that all these ampC calls really corresponded to E. coli chromosomal ampC, as the cefoxitin MIC for the isolate was only 8 mg/L, whereas cefoxitin MICs for E. coli with acquired plasmid AmpC enzymes are mostly .64 mg/L (PHE data on file). MinION and Illumina both found aacC2 and aac(6 ′ )-Ib-cr, agreeing with gentamicin and tobramycin resistance and a raised amikacin MIC. Both detected aadA5, but the organism was susceptible to streptomycin and this gene may not be expressed. Detection of dfrA17 by MinION and Illumina agreed with trimethoprim resistance. Double mutations in gyrA and parC, explaining high-level ciprofloxacin resistance, were detected by Illumina, not MinION. 
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CU7 (E. coli)
MinION and Illumina again detected bla CTX-M-15 , agreeing with an ESBL phenotype; bla OXA was absent and the isolate was more susceptible than those from CU5 and 6 to penicillin-inhibitor combinations. Both methods found bla TEM-1 . Phenotypic resistance to streptomycin agreed with detection of aadA1 and strA/strB by both methods, and aadA3 by MinION only. An ampC gene (bla ) was flagged by MinION, not Illumina. As with CU5, however, a low cefoxitin MIC (4 mg/L) contraindicated plasmid ampC and the result probably reflected miscalling chromosomal ampC. The ciprofloxacin MIC (0.25 mg/L) was slightly raised and a single mutation in gyrA was detected by Illumina only.
CU8 (E. coli) and CU9 (Enterobacter cloacae)
The E. coli from CU8 was resistant to ampicillin, amoxicillin/clavulanate and cefoxitin (MICs, 16-64 mg/L), with diminished susceptibility to cefotaxime (MIC 1 mg/L). Cefotaxime/cloxacillin synergy implied AmpC, as did the raised cefoxitin MIC (.64 mg/L). MinION flagged several acquired ampC genes, but these were not confirmed by Illumina sequencing, meaning that upregulation of chromosomal ampC is the likeliest explanation. CU9 contained E. cloacae with a cefotaxime MIC of 2 mg/L, reduced to 0.125 mg/L by cloxacillin, implying partial derepression of ampC, the commonest mode of oxyimino-cephalosporin resistance in this species. MinION flagged multiple acquired ampC genes and Illumina flagged bla ACT-24 , all probably reflecting mis-calling of chromosomal Enterobacter ampC. No other acquired genes were found in either CU8 or 9 in the isolates, agreeing with their general susceptibility.
CU10 (K. pneumoniae)
MinION and Illumina detected bla CTX-M-15 and bla OXA-1 , agreeing with an ESBL phenotype and amoxicillin/clavulanate resistance. Both also found bla TEM . MinION additionally flagged multiple bla SHV variants, whilst Illumina indicated bla SHV-28 and bla LEN-12 .
High gentamicin, tobramycin and amikacin MICs (8 -32 mg/L) accorded with detection of aacC2 and aac(6 ′ )-Ib-cr by both methods, with aacA4 additionally flagged by MinION. Resistance to streptomycin agreed with the detection of strA and strB by both methods and aadA3 by MinION only. Trimethoprim resistance accorded with the detection of dfrA14 by both techniques. qnrB and aac(6 ′ )-Ib-cr were found by both methods, but high-level ciprofloxacin resistance (.8 mg/L) more likely reflected gyrA and parC mutations, found only by Illumina.
Spiked urines
E. coli H141480453 had NDM and OXA-181 carbapenemases and was susceptible only to colistin and tigecycline. Synergy arose between EDTA and imipenem, reflecting metallo-b-lactamase inhibition, but not between cephalosporins and clavulanate or cloxacillin. The four sets of MinION data, directly from urine, closely matched Illumina sequencing (Table 3) . Thus, bla TEM , bla CTX-M-group-1 , bla OXA-48/181 , bla NDM and bla CMY b-lactamase were consistently identified, though with MinION flagging multiple matches within families, whereas Illumina identified single alleles. Among aminoglycoside determinants, rmtB was consistently found by both methods, as were aacC2, aac(6 ′ )-Ib-cr and strA/B;
Illumina found aadA2, aadA3 and aadA5 as did MinION run 3; MinION runs 1 and 2 flagged only one or two of these (aadA2 and aadA3 are closely related; aadA5 differs considerably). rmtB alone would confer pan-resistance to aminoglycosides, as observed. Trimethoprim resistance accorded with dfrA12 and dfrA17, found by Illumina and three of four MinION runs. aac(6 ′ )-Ib-cr and qnrS variants were consistently flagged by MinION and Illumina, but mutations in chromosomal gyrA and parC (reliably detected by Illumina only) are more likely to explain observed high-level fluoroquinolone resistance. The organism was sulphonamide resistant and Illumina detected sul1, while all MinION runs found both sul1 and sul2; tetracycline resistance agreed with the detection of tetA by Illumina and in three of four MinION runs. catB3, congruent with observed chloramphenicol resistance, was consistently flagged by MinION; Illumina detected a related gene, but with only 69% identity to catB3, and a novel variant may be present.
One hour of MinION sequencing delivered 0.2×, 3.75× and 6.96× coverage depth for spiked runs 1, 2 and 3, respectively ( Figure 4 ). To assess whether this detected resistance genes adequately, we reanalysed 1 h reads from runs 1 to 3 on ARMA software and those of run 4 with BLAST/CARD (its 1-D reads were unsuitable for ARMA). All the acquired resistance genes identified in runs 2, 3 and 4 were recognizable in the 1 h data, except for bla CMY in run 2 and strB in run 4. An ampC gene (bla LAT-1 ), was additionally identified in run 4. Lower coverage in run 1 precluded 1 h detection of several genes.
MinION sequencing of healthy urine spiked with E. coli from CU6 detected the same acquired genes as (i) Illumina sequencing of the isolate, and (ii) MinION sequencing direct from CU6, confirming that any bacteria and resistance genes in the urinary tract of the healthy urine donor did not distort results.
Discussion
Rapid pathogen profiling from clinical specimens, without culture, could facilitate better treatment and antibiotic stewardship. PCR diagnostics are under trial for this purpose, but can only seek limited numbers of targets. Sequencing could deliver a more comprehensive picture and we investigated if this was achievable with the MinION. Urine was taken as an exemplar, with a heavy load of infecting bacteria, thereby: (i) yielding sufficient DNA for MinION sequencing; (ii) minimizing the confounding effects of commensal bacteria and laboratory/reagent contamination on results; and (iii) ensuring a high bacterial cell/human cell ratio. Hasman et al. 7 previously applied Ion Torrent sequencing to urine, finding identical resistance genes as in the cultivated pathogens, but, with a 24 h turnaround, their method only modestly accelerated conventional workflows.
MinION can identify microorganisms 32, 33 and MinION sequences can predict resistances in cultivated bacteria. 34, 35 Advantages over other sequencing platforms are: (i) rapid turnaround; (ii) low capital cost; and (iii) small size. The technology remained under active development whilst the present studies were undertaken. The manufacturer's improvements, together with refinements in our sample preparation, delivered the stepwise gains illustrated in Figure 1 . Initial experiments, without human cell depletion (CU1), led to a large proportion of human reads and correspondingly low bacterial sequence yield. We therefore sought to enrich bacterial DNA, initially by 111 MinION sequencing for pathogen profiling
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w Microbiome DNA Enrichment (CU2 -4), which proved unsatisfactory. From CU5, we combined differential centrifugation, removing most human cells, with MolYsis technology to lyse residual human cells and remove their DNA. This allowed us to identify pathogens, and the same families of acquired resistance genes as found in pure cultures by Illumina, with good agreement to resistance phenotypes.
Most sequence analysis was post-run, using BLAST search and CARD database. However, the Metrichor WIMP and ARMA software, adopted late in these studies, allowed real-time analysis. With this approach, adding together times for analysis (1 h), sequencing (1 h), library preparation (3 h), DNA extraction and sample transport (2.5 h) suggests a total 7 -8 h turnaround, equating to one dosage interval for a 'typical', every 8 h, antibiotic. Further acceleration is feasible using the 15 min library preparation kit (as with spiked urine run 4) reducing turnaround to 4 h (Figure 4 ). This is similar to PCR methodology and would inform much earlier de-escalation and refinement of therapy than now. During the WIMP/ARMA-based analysis 32 Mb of 2-D sequencing data were generated, with almost 7× depth of coverage after 1 h (57 Mb of 2-D data with 11.37× depth were available after 2 h). Based on the equation of Lander and Waterman, 36 we calculate that 7× depth covers 99.905% of the E. coli genome (4.6 Mb), leaving little risk of missing an acquired resistance gene. Moreover, MinION sequencing error rates are diminishing rapidly (.90% identity with recent R9 pore chemistry). 37 Although the approach has great potential, challenges remain. First, we used heavily infected urines (.10 7 cfu/mL) to deliver 1 mg DNA required for sequencing, whereas significant bacteriuria is defined as .10 5 cfu/mL. Low-input procedures have been described and should address this issue 38 ; these reduce the DNA requirement for nanopore sequencing to 20 ng.
Secondly, we tested one urine sample per flow cell. While this offers flexibility, it is expensive, with cells costing US$500 -900 each. This is balanced (i) if a day's hospitalization is saved, or (ii) if expensive antibiotics can be avoided. Alternatively, ONT has introduced a PCR-free barcoding kit, allowing multiplexing of 12 samples; this would reduce the cost per sample, but would necessitate batching, extending turnaround.
Thirdly, allelic variants were poorly distinguished. In particular, the MinION-based pipeline: (i) failed to detect mutations associated with fluoroquinolone resistance or ampC up-regulation (likely to have been present, e.g. in the E. coli from CU8 and the E. cloacae from CU9); (ii) flagged multiple alleles (e.g. of bla TEM , bla SHV , bla CTX-M , bla NDM ), whereas Illumina indicated single types; and (iii) confused acquired (plasmid-mediated) and endogenous chromosomal ampC and bla SHV/LEN . Distinguishing bla NDM or bla CTX-M variants is unimportant, as all alleles have similar resistance implications; however, SNPs determine hydrolytic spectrum and inhibitor vulnerability within the TEM, SHV and GES families, thereby determining whether a therapy is appropriate or not. In the case of AmpC, plasmid types are copiously expressed and have clear resistance association, whereas the implications of chromosomal types depends on their level of expression, which is determined by the promoter sequence in E. coli or by mutation of regulatory genes (principally ampD) in species with inducible ampC expression, e.g. E. cloacae. To complicate matters further, the plasmid-mediated types, which occur across species, are chromosomal escapes from other species-CMY-2, the commonest, is from Citrobacter freundii and DHA-1 from Morganella morganii. There are potential ways to address the challenges of distinguishing closely related variants and predicting AmpC expression. SNPs and sequence variants can be called using MinION data, 39 though this is slow. In future, reads aligning to CARD could be isolated and polished to improve consensus accuracy, facilitating precise identification. What is more, long MinION reads can give context to the position of resistance genes, potentially enabling differentiation between plasmid-borne and chromosomal ampC genes. Optimally, MinION reads will enable the assembly of complete plasmids and in some cases, single reads will cover the full length of a plasmid.
Fourthly, a gene may be present, but fail to cause resistance, owing to poor expression, silencing or inactivation. MinION and Illumina found aadA5 in CU6, but the E. coli isolate was streptomycin susceptible. Tyson et al. 40 previously noted poorer genotypephenotype concordance for streptomycin than for other resistances (81.3% versus 100%).
Lastly, optimizing the cut-off to call only the 'true positive' results for resistance genes is challenging. We used 90% identity for Illumina and (owing to lower base-calling accuracy) 80% identity for MinION. This lower cut-off probably explains the larger number of misidentifications of plasmid ampC by MinION and the calling of catB3 in E. coli H141480453 by MinION, but not Illumina. A technical aspect, independent of MinION, was occasional misdetection of resistance genes due to inclusion of flanking regions of integrons in CARD (not shown). This might be resolved by adjusting cut-offs, but is better addressed by stricter database curation. All the CU samples tested in this study were infected with single pathogens. Polymicrobial UTIs were not sought; however, MinION data can identify and differentiate multiple species in metagenomic samples. 41 Multiple strains of the same species would be harder to distinguish, but all their resistance genes would be represented in the sequence, whereas conventional culture would be liable to select randomly and test one of the strains present.
Given the improvements achieved already, we believe that the technology can be enhanced to overcome these challenges. If so, MinION profiling from patients with urosepsis could allow beneficial refinement of antibiotic regimens within the first dosage interval after clinical diagnosis.
